Guanine eOligo Test Platform
|
Slash the cost of
advanced blood tests
and precision health AI
|
by up to 90%
|
|
|
WHO WE ARE |
Our eOligo platform reduces the cost of advanced blood tests by up to 90% Guanine’s eOligo platform drives step-function cost reductions by collapsing what are usually three separate workflows—immunoassay, molecular (PCR/NGS), and chemistry/LC-MS—into a single disposable cartridge with an electrochemical readout. Instead of paying for multiple reagent kits, multiple instruments, and multiple tech handoffs, users employ one automated cartridge and one compact reader. Reagents are miniaturized, optics are eliminated, pre‑centrifugation is not needed, and an electrochemical biosensing technique quantifies everything—proteins, small molecules, cells, nucleic acids, even redox materials—off the same whole-blood draw at the point of care. Guanine’s platform reduces costs from “complex capital + expensive chemistry” to “inexpensive disposable + labor-free short run time,” which is why the per-test total can fall dramatically. Our eOligo platform provides unprecedented Dx capabilities |
Single whole-blood draw yields proteins, nucleic acids, metabolites, cells and redox materials in one run.
Benefit: Replace multi-instrument workflows with one fast, inexpensive consolidated reader and automated cartridge. |
Attomolar sensitivity via millions of stackable eOligo tags + filter concentration + magnetic enrichment + EC readout.
Benefit: Detect disease signals earlier when treatment is more effective and less expensive. |
Up to 144 targets and controls per cartridge with a 6 x 6 electrode array and 4 species per electrode using peak-coded probes.
Benefit: Broader clinical insight without extra samples, time, or cost. |
Absolute copies/mL and pg/mL with baseline/post-hybridization SWV calibration.
Benefit: Trend biology, set thresholds, and power real dose/therapy decisions at a fraction of the cost. |
Small, heater-free reader that operates the test protocol and transmits test results.
Benefit: Bring inexpensive advanced testing to the bedside, clinic, or field—no lab required. |
Turn a single whole-blood draw into a fast, multi-omic feature vector—ready to feed Precision Health AI models at the point of care.
Benefit: Rich, quantitative, longitudinal signals dramatically improve risk prediction and treatment optimization while lowering cost. |
Advanced blood tests for cancer, chronic diseases,
complex infections, drug testing, and precision health AI
are too expensive for widespread use
|
ADVANCED BLOOD TESTS: “ Ultrasensitive detection of circulating tumor DNA or other low-abundance biomarkers in blood could transform cancer diagnostics, but the challenge is to develop cost-effective platforms that maintain high sensitivity without requiring expensive infrastructure."
|
PRECISION HEALTH AI “ The bottleneck for AI in precision health isn’t the algorithms—it’s the lack of affordable, multiplexed diagnostics that can detect low-concentration molecules like RNAs, proteins, and metabolites in a single assay. Until we solve this, precision medicine will remain a niche.”
|
Guanine fills the void
|
WHO CAN BENEFIT
|
OEM Dx Developers Drug Dx Developers Sepsis Dx Users Guanine enables unprecedented multi-analyte combinations—simultaneously quantifying proteins, nucleic acids, metabolites, cells, redox markers, and even drugs from one whole-blood draw. |
|
|
OEM Dx developers can move their biomarkers to white-label cartridge panels that collapse multi-instrument workflows into a single run. This allows:
|
Drug Dx developers gain true PK/PD bundles (drug ± metabolite + host injury/inflammation + tumor/pathogen load) for MRD, CDx, and TDM in the same visit including:
|
Sepsis Dx from POC diagnosis and treatment tools using a trio of purpose-built cartridges covers the full decision arc:
|
|
Guanine's eOligo technology enables a
new generation of rapid, simple and inexpensive multi-analyte tests from a single sample |
|
Guanine's multi-analyte testing provides
faster diagnosis and improved treatment decisions
|
OUR UPCOMING OEM PRODUCTS
|
OEM Cartridges and Reader OEM Assay Development Tools White Label Cartridges
The system centers on two disposable multi-analyte cartridges: Swift16 for rapid multiplex triage and Deep36 for ultra-sensitive, high-plex assays. Each workflow performs on-cartridge filtration/fractionation, streptavidin magnetic-bead capture using biotinylated aptamers/oligos (PolyG detection sequence-linker-70-mer), magnetically assisted washing, and guided delivery to carbon working electrodes to form bead–analyte–electrode “sandwiches.” 
Swift16 Cartridge — 20-min quantitative panel for rapid host/drug/metabolite triage. Benefit: One tube, bedside results in 20 minutes to quickly stratify risk and guide empiric therapy, replacing multiple lab tests with a single, low-cost run. Description: A compact 16-electrode cartridge for rapid, multiplexed host-protein, small-molecule (TDM), and redox testing from a single 100 µL EDTA whole-blood draw—no centrifuge required. Plasma is generated on-cartridge via micro-separation, then analytes are captured with biotinylated aptamers/oligos (PolyG–linker–70-mer) on streptavidin beads/electrodes; detection uses square-wave voltammetry (SWV ~1400 mV/s) with a stored baseline pre-hybridization scan and a post-hybridization read in low-cost NaOAc read buffer. Design targets: 20-minute TAT, femto-level LoD for proteins, 16 sites with up to ~64 EC channels (multi-signal addressing) including QC/self-calibration electrodes; magnet oscillation for fast on-rates; optional competitive assays for tacrolimus/vancomycin/DOACs; single-use fluidics with hemolysis/flow adequacy checks. RUO/IVD-intent configuration available for OEM partners Deep36 Cartridge — 60-min quantification of ultra-low analytes for early detection. Benefit: Detects and quantifies attomolar nucleic acids and femtomolar proteins from whole blood in ~60 minutes, enabling earlier, more confident clinical decisions than culture- or lab-bound workflows. Description: A high-sensitivity 36-electrode cartridge that processes 5 mL EDTA whole blood to deliver redox first, then host-protein aptamer assays, and finally direct-from-blood pathogen RNA with on-cartridge pre-concentration. A temporary, dissolvable alginate micro-sieve retains cells/microbes while proteins pass; the sieve is then dissolved (EDTA/EGTA) to release retentate for lysis → hybridization at room temperatureand capture via biotinylated 70-mer probes on streptavidin beads/electrodes. Detection uses SWV (~1400 mV/s) with baseline/detect scans in NaOAc read buffer; attomolar-class LoD (design target) and up to ~144 EC channels (multi-signal addressing) including RNase P/process spikes, negative controls, and self-calibration electrodes. Built-in magnet mixing, and fluidic isolation prevent cross-chemistry interference. RUO/IVD-intent OEM configurations supported. Develop96 Kit — 2.5 to 4 hours quantification of up to 16 targets in duplicate wells for RUO assay design and optimization. Benefit: Rapidly prototype panels and transfer conditions to cartridges with minimal rework. Description: A low-cost RUO 96-well sensor microtiter kit that lets teams rapidly screen capture/detector eOligos and aptamers, optimize hybridization/kinetics, and lock LoD, linearity, cutoffs, and multiplex peak spacing on real electrochemical sensors; bundled controls and SOPs mirror cartridge chemistry so methods transfer cleanly to Swift16/Deep36 with minimal rework, compressing development cycles from months to weeks. Design targets: nucleic acids ≤10 aM LoD, proteins ≤100 fM, high linearity, and low intra-plate CV in whole-blood matrices. Each well supports up to 4 targets via peak-coded quadruplex tags (multi-analyte reads on a single electrode). Guanine provides ligand-conjugation services—ready-to-run magnetic microparticles (streptavidin or carboxyl) loaded with biotinylated eOligos/aptamers or EDC/NHS-coupled antibodies, plus pre-functionalized sensor electrodes. Potential OEM Multi-Analyte POC Applications |
|
Guanine’s OEM test platform fills a void by quantifying 16 to 96 low concentration nucleic acids, proteins, small molecules, cells and redox materials in a single assay with a $500 mobile device |
|
|
OUR UPCOMING SEPSIS PRODUCTS
|
Rapid Tests (Inflammation, Pathogen ID/AMR, Phenotype) Sepsis Tests
Guanine's suite of culture-free sepsis tests provide rapid information to reduce mortality, hospital stay and costs. 
Sepsis Inflammation — A 20-minute, whole-blood panel (e.g., PCT/CRP/IL-6 ± lactate proxy) that quantifies host response for rapid sepsis triage at the point of care. Benefit: Enables immediate risk stratification and empiric therapy decisions without waiting on culture or central-lab chemistry. Description: A rapid triage panel measuring PCT, CRP, IL-6 plus lactate from 100 µL whole blood on Swift16, using aptamer/oligo capture (PolyG–linker–70-mer on streptavidin) and SWV detection with baseline/detect scans in NaOAc read buffer. Design specs: 20-minute TAT, femto-class sensitivity for proteins, on-cartridge plasma micro-separation, built-in QC (self calibrated electrodes, label/flow checks), and result outputs suitable for admit vs discharge and antibiotic stewardship pathways. Delivered RUO initially with OEM pathways to IVD. Sepsis ID/AMR — A ~60-minute, direct-from-blood assay that delivers quantitative pathogen ID (copies/mL) and resistance-gene burden (e.g., KPC/NDM/mecA/van) on a single cartridge. Benefit: Supports early, evidence-based escalation or de-escalation of antibiotics while confirmatory culture/MIC proceeds. Description: A direct-from-blood (60-min) cartridge that filter concentrates s pathogens from 5 mL whole blood, performs rapid lysis, magnetic capture and separation and uses multiplexed eOligo electrochemistry to deliver quantitative species load (copies/mL) alongside quantitative resistance-gene load (i.e., KPC/NDM/OXA-48, mecA/C, vanA/B, CTX-M/ESBL), enabling immediate escalation or de-escalation while phenotyping proceeds. It’s designed for the Mobile Reader, requires no thermocycler or optics, and feeds stewardship rules (bug–gene–load) to move from “broad” to “appropriate” therapy inside the decision window. Key features: direct-from-blood genotypic insight; up to 36 targets (1–4 species per electrode); quantitative loads for trending/severity; room-temperature workflow; LIS/EMR-ready outputs for surveillance dashboards. Sepsis Phenotype — A ~90-minute culture-free phenotyping cartridge that tests multiple antibiotics in parallel and computes an early S/I/R surrogate via an Inhibition Index. Benefit: Provides same-day functional susceptibility guidance to refine therapy choices long before conventional MIC results are available. Description: A culture-free phenotyping cartridge that turns the same draw into a functional S/I/R surrogate in ~90 min by splitting an enriched aliquot into a no-drug control and parallel antibiotic chambers, running a short, timed exposure (ambient with optional 34–36 °C micro-heat for slow-kill GP agents), applying a viability gate, and reading multiplexed eOligo signals at scheduled timepoints (e.g., t60/t90/t180) to compute an Inhibition Index per drug. Standard layouts cover 3–5 first-line antibiotics (triplicates) on one cartridge; the Expanded option adds more drugs or two levels per drug. It runs on the Mobile Pheno Reader and complements Sepsis ID/AMR by confirming or refining early gene-guided choices with same-day functional data while MIC is pending. Key features: parallel multi-drug exposure on-cartridge; repeat rescans without signal loss (reversible 8-oxoG tags); viable-load quant for each species; configurable call thresholds with confidence flags; seamless handoff to stewardship for protocolized therapy changes. |
Guanine's eOligo signal amplification with filter concentration
of 5 mL samples quantify low level pathogens and
drug resistance genes without culture to reduce mortality,
hospitals stay, and cost per patient by 200% - 300%
|
OUR UPCOMING INSTRUMENTS
|
Mobile Readers Assay Development Workstation Detection and Development Instruments
Guanine offers a modular electrochemical biosensing platform that turns a single whole-blood sample into multiplexed, quantitative results across nucleic acids, proteins, small molecules, cells, and redox markers—using a compact reader with connected analytics. Guanine's Mobile Readers execute baseline and post-capture square-wave voltammetry (SWV), converts Δpeak signals to concentrations via lot-specific calibration and internal controls, and securely exports results (LIS/EMR/cloud) for point-of-care use, companion diagnostics, and assay-developer OEM programs. 
eOligo Mobile Reader — Compact eOligo analyzer for automated Swift16/Deep36 operation.
Benefit: Low capital cost enables broad deployment and fast scale-up. Description: A portable electrochemical reader that auto-identifies Swift16 or Deep36 via NFC/QR, drives magnet oscillation, controls hybridization, and executes SWV baselines + detection scans (with optional startup CV/cyclic-SWV on a calibration electrode to verify film/electrode health). It manages multi-signal addressing across electrodes, enforces QC, and outputs results with flags and composite scores. Connectivity: USB-C, BLE/Wi-Fi, and HL7/PDF/API export; onboard encryption/audit logs; barcode support for sample/reagent traceability. Small footprint, low power, and sealed waste handling enable near-patient use; firmware exposes an OEM SDK (raw signals, QC, channel maps) for customized assays and LIS integration. eOligo Mobile Phenotype Reader — Universal compact eOligo analyzer for Swift16/Deep36/Pheno36 Benefit: Low capital enables rapid decisions for appropriate sepsis treatment at the POC. Description: A portable, phenotype-enabled eOligo analyzer for Swift16, Deep36, and Sepsis Pheno96 cartridges that auto-identifies the cartridge via NFC/QR, drives magnet oscillation/hold, orchestrates hybridization and on-cartridge drug-blister/valve timing, and executes SWV baselines + detection scans (with optional startup CV/cyclic-SWV on a calibration electrode to verify film/electrode health). Purpose-built for phenotyping, it adds a localized 34–36 °C micro-heat zone over the phenotype chambers, a viability-gate LED module for PMA-like steps, and a “kinetics pack” that schedules multi-timepoint rescans (e.g., t60/t90/t180/t270) to compute an Inhibition Index and output an early S/I/R surrogate with configurable thresholds. The reader manages multi-signal addressing across electrodes, enforces QC with reagent/sample barcodes, and returns results with flags and composite scores; connectivity includes USB-C, BLE/Wi-Fi, HL7/PDF/API export, plus onboard encryption/audit logs for compliance. A small-footprint, low-power design with sealed waste handling supports near-patient use, and the firmware exposes an OEM SDK (raw signals, QC hooks, channel maps, drug/exposure recipes) for custom assays and LIS integration. eOligo Lab Workstation — Benchtop EC + magnetics platform with SDK for method development. Benefit: Shorten time-to-menu by screening probes, kinetics, and recipes in hours. Description: A benchtop microtiter supported electrochemistry + magnetic separation devices that executes full eOligo workflows (filtration/capture, wash, SWV), exposes raw voltammograms for analysis, to prototype cartridge protocols, It’s the fastest way to iterate, validate, and hand off robust methods to manufacturing or OEM partners. The workstation is RUO and employs off-the-shelf components (bench potentiostat, magnet separator, plate shaker, filter holder, optional micro-heater), so labs can deploy quickly without custom capital. It supports up to 4 targets per well using multiplex peak coding, and Guanine’s microparticle/electrode ligand-conjugation services ensure reproducible capture chemistry from plate to cartridge. |
|
eOligo Lab Workstation |
eOligo Mobile Reader and OEM Cartridge (Upcoming) |
|
|
|
OUR SECRET SAUCE |
Guanine has patented the electric oligonucleotide (eOligo) Guanine’s platform replaces bulky optical readers with a miniaturized electrochemical reader. Each analyte is captured on a prefabricated magnetic particle bearing a 70-mer capture probe and a stackable, reversible quadruplex tag. These complexes hybridize to complementary 70-mer recognition probes on a screen-printed carbon electrode (SPCE) inside a disposable cartridge. Detection is performed by square-wave voltammetry (SWV) in a simple buffer (sodium acetate pH 9). The quadruplex tags — 8-oxoG, 8-oxoA, 6-oxoC and 8-oxoT — have distinct oxidation potentials, producing four separate peaks per working electrode. Because the tags are reversible, the same electrode can be scanned before and after sandwich formation to generate a built-in calibration curve. |
eOligo Detection Tags
|
Stackable Oligonucleotide Molecule Tags — Attaining Ultra-Low LOD
Guanine’s platform uses engineered tag oligonucleotides that can “stack” on each captured analyte. Instead of a single electroactive moiety per binding event, up to 100 million electroactive molecules can bind to one target using a 3 micron particle. This produces massive signal amplification without enzymes or optical labels, pushing the detection limit down to the attomolar range and making trace biomarker quantitation feasible.
Benefit: True ultrasensitivity without PCR, enzymes, or optics — enabling early detection of disease markers |
Quadruplex Structure — Reversible and Stronger Oxo Signals
The tag chemistry is based on guanine-like “quadruplexes” (e.g., 8-oxoG/A/T and 6-oxoC). These folded four-strand structures produce high, sharp oxidation currents in square-wave voltammetry. Because the quadruplexes refold after oxidation, their signals are reversible rather than being consumed as in standard single-stranded tags. Benefit: A stronger, more stable electrochemical signal with minimal drift, enabling repeated scans and quantitative calibration. |
Long 70-mer Capture Sequences — Specific, Fast Hybridization
Both the bead-bound capture oligos and electrode recognition probes are long (≈70 nucleotides). This confers strong, specific hybridization kinetics even at room temperature, while being incompatible with PCR primers and thus avoiding carry-over contamination from amplification workflows. Benefit: High specificity and speed in complex biological matrices; works at ambient conditions without thermal cycling. |
Electric Detection Signals
|
High Signal-to-Noise Resolution
Guanine’s eOligo tags generate unusually sharp, high-amplitude oxidation peaks. Combined with magnetic enrichment, dual 70-mer hybridization, and on-electrode calibration, background currents and non-specific binding are suppressed before the voltammetric scan. The result is a very high signal-to-noise ratio where each target produces a clean, distinct peak that stands out from the baseline even at attomolar concentrations.
Benefit: This high resolution translates to greater sensitivity and specificity. It also improves quantitative accuracy, making the platform suitable for clinical decision-making where small changes in biomarker levels matter. |
Four Distinct, Well-Separated Tag Channels per Electrode
The platform exploits four different oxo-tag chemistries whose oxidation peaks occur at separated potentials. This lets a single screen-printed electrode resolve four independent signals from a single sample spot without peak overlap.
Benefit: True multiplexing — up to four analytes (or three analytes + control) per electrode; on a 6×6 array that scales to 144 targets per disposable cartridge. |
Same-Electrode Calibration — Baseline and Drift Control
Because the tags are reversible, the electrode can be scanned before and after sandwich formation to record its baseline and adjust for fouling. This “on-chip” calibration corrects for matrix effects and electrode variability automatically. Benefit: Improved reproducibility and quantitative accuracy between runs, even in untrained hands or varied sample types. |
Automated Test Process
|
Simple, Reliable, and Portable Cartridge Workflow at Room Temperature
The assay runs in a small disposable cartridge that integrates filtration, lysis, magnetic separation, and the electrode. There’s no optics, no enzymes, and no heating — just a compact potentiostat and room-temperature hybridization.
Benefit: A technician-free, point-of-care platform that delivers lab-grade sensitivity and multiplexing at a fraction of the cost, easily deployable in clinics, field settings, or even home monitoring. |
Multi-Analyte Types for Advanced Blood Tests
Guanine’s cartridge is designed to work with nucleic acids, proteins, small molecules, cells, and native redox-active biomarkers in the same scan. The quadruplex tags are analyte-agnostic: the same electrochemical reader and disposable cartridge handle DNA/RNA targets, protein epitopes, metabolites, and cell-surface markers simply by changing the capture chemistry on the beads and electrode.
Benefit: This flexibility lets labs and developers build multi-omic diagnostic panels on a single platform—combining genetic, proteomic, and metabolic markers into one test. It reduces cost and turnaround time, provides richer clinical insight per sample, and supports precision health AI by feeding a broader range of biomarker data into predictive models. |
Automated Reader
The platform’s compact electrochemical reader automatically tunes key square-wave voltammetry parameters—such as frequency, amplitude, and step potential—for each disposable cartridge. This built-in optimization accounts for electrode variability, sample matrix effects, and temperature, so end users don’t need to manually adjust settings or have electrochemistry expertise. Benefit: Automated optimization delivers consistent, high-quality data across operators and environments. It minimizes training requirements, ensures reproducible performance at scale, and makes the system truly “plug-and-play” for hospitals, clinics, and field deployments. |
Sample Applications
|
Drug Resistance and MIC Value
Guanine measures the concentrations of specific microorganisms such as K.pneumoniae and drug resistant genes such as Klebsiella pneumoniae carbapenemase (KPC). Resistant species produce a higher signal from the ratio of resistant genes per bacteria and can be converted to MIC value.
|
Microbe Viability
Guanine measures ultra-low LOD is attained by filter concentrating a 5 mL volumes followed by magnetic separation and amperometric quantification of eOligos on magnetic particle-target-electrode sandwiches. Viability and growth rates can be measured from a second sample to determine the increase in concentration over a fixed time interval such as 3 to 6 reproduction cycles
|
|
Precision Health AI
Low level concentrations of cancers, microbes, host response, genetic makeup and drug levels can be rapidly measured from a single blood sample at the Point of Care. Test results combine with other information to provide a new generation of precision health interventions. |
DNA Methylation and Methylation Rate
Our eOligo biosensor can be used to quantify specific genes and associated 5mC and 5hmC without bisulfate conversion, PCR or sequencing. Methylation rate can be easily determined using a second sample at a later time to measure the rate of increase or decrease. |
|
OUR
PUBLICATIONS |
Guanine's patented technology has strong intellectual property protection offering a significant barrier to entry for competitors. Patents have been granted in the US and Canada and pending in Europe. Data from a CDC grant can be found in the following publications. |
|
PATENT
Bioanalyte Signal Amplification and Detection with Artificial Intelligence Diagnosis Download US 11,105,801 (granted) CA 3,068,084 (granted) EP 3679362 (pending) |
|
PATENT
Ultra-Sensitive Bioanalyte Quantification from Self-Assembled Quadruplex Tags Download US 11,175,285 (granted) CA 2,954,115 (granted) |
|
|
PUBLICATION
Detection of Pathogens and Antimicrobial Resistance Genes at Low Concentration via Electrochemical Oligonucleotide Tags Download Gordon, N., R. Bawa and G. Palmateer. (2023). Detection of pathogens and antimicrobial resistance genes at low concentration via electrochemical oligonucleotide tags. Eng. Proc. 35:28. https://doi.org/10.3390/IECB2023-14584 (7 pages) |
|
PUBLICATION
Carbapenem-Resistant Enterobacteriaceae Testing in 45 Minutes using Oligonucleotide Detection Tags Download Gordon, N., R. Bawa, G. Palmateer, M. Rajabi, J. B. Gordon, N. M. Kotb, R. Balasubramaniyam and B, R. Gordon (2023). Carbapenem-resistant Enterobacteriaceae testing in 45 minutes using oligonucleotide detection tags. In: R. Bawa et al., (eds.), Advances in Medical Imaging, Detection, and Diagnosis, Jenny Stanford Publishing, Singapore, chapter 26, pp. 813-828 |
|
|
OUR
MANAGEMENT TEAM |
Guanine's pedigree evolved from nanotech pioneers, pathogen testing, spearheading Early Warning Inc, a NASA biosensor spinoff and incubating in Mount Sinai's Elementa Labs. |
|
Neil Gordon B.Eng, MBA is Guanine’s founder and inventor of the electric oligonucleotide detection platform. He was one of the first business consultants in nanotechnology and created a boutique consulting practice at Sygertech. He co-founded the Canadian NanoBusiness Alliance, and set up a high throughput nanoimprint lithography center at Canada’s CNRC. He worked with ITRI, Taiwan’s national lab to investigate how semiconductors can detect low concentration biological molecules. He was head of commercialization for the NASA-led CANUS Consortium and spun out Early Warning Inc. He led a team to develop and commercialize NASA’s carbon nanotube biosensor to detect DNA/RNA in waterborne pathogens using an automated sample collection and detection device. He subsequently invented the electric oligonucleotide which detected any type of trace biomolecules at a fraction of the cost of NASA’s technology. He founded Guanine Inc which was incubated at Mount Sinai’s Elementa Labs to apply the platform for POC advanced blood tests. Early in his career he worked for software, hardware and instrumentation companies. |
Raj Bawa
MD, PhD Vice President |
Raj Bawa MD, PhD is Guanine’s VP and has provided guidance for three patents, was principal investigator on Guanine’s CDC grant and coordinates publicity/networking activities. Trained as a microbiologist and biochemist, he is an inventor, physician, author, speaker, entrepreneur and professor. He is also a registered patent agent in good standing licensed to practice patent law before the US Patent & Trademark Office. He is currently a scientific advisor to Teva Pharmaceutical Industries, Israel and full professor at Northern Virginia Community College, Annandale, VA. He was an adjunct professor at Rensselaer Polytechnic Institute (Troy, NY). Dr. Bawa held various positions at the US Patent & Trademark Office, including primary examiner. He has served as a principal investigator of various NCI research grants. A pioneer in clinical nanomedicine and precision medicine, he was awarded the Lifetime Achievement Award from the American Society for Nanomedicine. He has authored over 100 publications, and edited 10 texts in medicine, biotechnology, patent law and nanotech, and was chair of 14 annual Road from Nanomedicine to Precision Medicine international conferences. He serves on the editorial boards of numerous peer-reviewed international journals, including serving as an associate editor of Nanomedicine (Elsevier). |
Garry Palmateer M.Sc.
Vice President |
Garry Palmateer, MS is Guanine’s VP and has extensive experience in microbiology labs performing assays, undertaking testing services and developing testing products. He provided analytical support, supervision, consulting and new study methods for Ontario Government laboratories in the Ministry of Environment and Ministry of Health. He oversaw remediation for E.coli and cryptosporidium outbreaks. He founded GAP EnviroMicrobial Services and provided services for the Environmental Protection Agency and the American Industrial Hygiene Association. He was nominated for a General Motors merit award for determining multiple sources of a Legionella pneumophila outbreak. At Early Warning, he developed the test protocol, co-developed the sampling and testing product. He developed the test protocol at Guanine and oversaw test QA in a CDC grant. |
|
OUR
HISTORY |
Guanine's predecessor company Early Warning Inc. was spun out of NASA Ames and evolved into our third generation platform. Guanine was incubated at Mount Sinai Health System's Elementa Labs. |
Nanotechnology pioneers NASA’s Meyya Meyyappan, chief scientist for exploration technology and former director of the Center for Nanotechnology at Ames Research Center (left) and Guanine's and Early Warning’s President Neil Gordon (right) examine a prototype of NASA’s nanotechnology-based biosensor licensed to Early Warning. (Source: NASA)
|
Mount Sinai Health System's Elementa Labs alumni JelikaLite President Katya Sverdlov (left) and Guanine President Neil Gordon (right) are featured presenters at a New York City event.
|
Our Gen 1 platform used NASA's carbon nanotube sensor with an automated instrument that filter concentrated 10L of potable water. It captured target pathogens with magnetic particles which were magnetically separated in advance of detecting guanine molecules in lysed pathogen RNA. Our Gen 2 platform used a low cost carbon electrode that detected eOligos denatured from a magnetic particle-target-amplification particle sandwich. Our current Gen 3 platform saves valuable time by attaching targets with magnetic particles bound with ligands and millions of eOligos which form sandwiches on a carbon biosensor electrode. eOligos are pre-made into quadruplexes for a stronger 8-oxoguanine detection signal.
|
CONTACT
US |
Send us a message by email or using the following form. |
|
Guanine Inc. 7 University Place, Suite B210 Rensselaer, NY 12144-3463 Telephone (514) 813-7936 [email protected] |
|
